scholarly journals Mapping HIV/AIDS High Risk and Vulnerable People in Communities’ Most at Risk Population

2020 ◽  
Vol 9 (5) ◽  
Author(s):  
Doreen Nekesa Busolo ◽  
Samuel Ngigi
Keyword(s):  
At Risk ◽  
High Risk ◽  
Risk Population ◽  
Vulnerable People ◽  
Hiv Aids

No Access to Services: The Struggle of Injection Drug Using Women in Abusive Relationships

2017 ◽  
Author(s):  
Emily Macgillivray
Keyword(s):  
At Risk ◽  
Substance Use ◽  
High Risk ◽  
Risk Behaviors ◽  
Service Providers ◽  
Target Population ◽  
Injection Drug ◽  
High Risk Behaviors ◽  
Marginalized Women ◽  
Hiv Aids

Women who experience violence and are at risk for HIV/AIDS are a multiply marginalized population which the majority of service providers ignore or feel they do not have the resources to deal with. Furthermore, while the Canadian government issues reports on violence against women, it does not provide an analysis of the intersection between violence HIV/AIDS. Women who are at risk for HIV due to injection drug use are particularly vulnerable when in a violent relationship; most women’s shelters have zero tolerance policies for substance use leaving these women isolated. By examining how substance use increases HIV risk for women who experience violence, the high risk behaviors associated with violence, and the high risk behaviors associated with substance use, multiply marginalized women’s needs become clearer. Service providers for multiply marginalized women must always consider the ramifications of their policies, as well as the ideologies that their policies are based on so that they can effectively help their target population. To address the needs of multiply marginalized women, drastic changes need to be made to the current shelter system: shelters need to examine their ideological foundation and analyze what stigmas their current policies support. Coordinated efforts are needed between multiple service providers to address the challenges that these often forgotten women face.

Satisfaction with health services for STIs, HIV, AIDS among a high-risk population in West Africa

AIDS Care ◽  
2008 ◽  
Vol 20 (3) ◽  
pp. 388-394 ◽  
Author(s):  
D. Morin ◽  
G. Godin ◽  
M. Alary ◽  
M.-R. Sawadogo ◽  
M. Bernier ◽  
...  
Keyword(s):  
High Risk ◽  
Health Services ◽  
West Africa ◽  
High Risk Population ◽  
Risk Population ◽  
Hiv Aids

Oral cancer in Hong Kong: identifying and managing the ‘high-risk’ population

2018 ◽  
Vol 9 (3) ◽  
pp. 116-121 ◽  
Author(s):  
Peter Thomson ◽  
Richard Su ◽  
Siu-Wai Choi
Keyword(s):  
At Risk ◽  
Hong Kong ◽  
High Risk ◽  
Oral Cancer ◽  
High Risk Population ◽  
Risk Population ◽  
Oral Carcinogenesis

How research can help identify those most at risk of oral carcinogenesis.

scholarly journals The effectiveness of tenofovir-based pre-exposure prophylaxis for prevention of HIV acquisition among Sub-Saharan African women at high risk: a systematic review

2021 ◽  
Author(s):  
Grant Murewanhema ◽  
Moffat Malisheni ◽  
Noah Fongwen Takah
Keyword(s):  
Systematic Review ◽  
At Risk ◽  
High Risk ◽  
Hiv Infection ◽  
Current Evidence ◽  
High Risk Population ◽  
Risk Population ◽  
Vaginal Gel ◽  
Sub Saharan ◽  
Exposure Prophylaxis

Abstract Background Women in Sub-Saharan Africa (SSA) are disproportionately affected by the HIV epidemic. In 2019, they constituted 59% of new infections; thus, they remain a key population for control. Public health interventions to prevent acquisition of HIV in this high-risk population are urgently needed. Tenofovir-based pre-exposure prophylaxis (TFV-PrEP) has been shown to reduce HIV infections in other key populations. However, comprehensive evidence regarding TFV-PrEP effectiveness in women living in SSA has not been determined. Therefore, we undertook a systematic review to determine the effectiveness of tenofovir-1% (TFV-1%) vaginal gel, oral tenofovir (TFV) and tenofovir-emtricitabine (TDF-FTC) pre-exposure prophylaxis for primary acquisition of HIV in at-risk women living in SSA.Methods OVID MEDLINE, EMBASE, CENTRAL, Web of Science and Clinical Trials.gov were searched for eligible studies from 01 January 2020 to 31 July 2020. Only randomised controlled trials (RCTs) conducted in women living in SSA were included. Measures of effectiveness (hazard ratios (HR), incidence rate ratios (IRR)) were extracted from individual studies to determine the effectiveness of TFV-PrEP in preventing HIV infection among at-risk women living in SSA.Results From 2002 non-duplicate articles, four RCTs evaluating the effectiveness of one or more of the interventions against placebos were included. TFV-1% vaginal gel, oral TDF or TDF-FTC were not effective in preventing the acquisition of HIV infection in women living in SSA. However, poor adherence by study participants could have confounded the true effectiveness of TFV-PrEP in this high risk population. Meta-analysis was not conducted given the limited number of eligible studies identified from the search.Conclusion The current evidence does not support the effectiveness of TFV-PrEP for HIV in SSA women. More studies aimed at addressing factors driving low adherence to HIV interventions in this high risk population are urgently needed in order to improve the design of future RCTs leading to the determination of more reliable estimates of TFV-1% vaginal gel or oral TDF or TDF-FTC effectiveness.Protocol registration: This systematic review was not registered in PROSPERO.

Sign in / Sign up

Export Citation Format

Share Document